Get started
Author

Philip Huxley

Observed names: P. HUXLEY, P. Huxley, PHIL HUXLEY
OpenAlex ID: A5055316795
Recent advances in matrix metalloproteinase inhibitor research
1996 · R. Paul Beckett, Alan H. Davidson, et al. · Drug Discovery Today · 281
Preclinical and Clinical Studies of MMP Inhibitors in Cancer
1999 · ALAN H. DRUMMOND, PAUL BECKETT, et al. · Annals of the New York Academy of Sciences · 221
Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor
1995 · Frank Grams, Mike Crimmin, et al. · Biochemistry · 167
The application of molecular similarity calculations
1990 · Catherine Burt, W. Graham Richards, et al. · Journal of Computational Chemistry · 125
MMAE Delivery Using the Bicycle Toxin Conjugate BT5528
2020 · Gavin Bennett, Amy Brown, et al. · Molecular Cancer Therapeutics · 106
Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads
2020 · Gemma E. Mudd, Amy Brown, et al. · Journal of Medicinal Chemistry · 80
1.8‐Å Crystal Structure of the Catalytic Domain of Human Neutrophil Collagenase (Matrix Metalloproteinase‐8) Complexed with a Peptidomimetic Hydroxamate Primed‐Side Inhibitor with a Distinct Selectivity Profile
1997 · Michael Betz, Philip Huxley, et al. · European Journal of Biochemistry · 80
Evaluation of the effort-related motivational effects of the novel dopamine uptake inhibitor PRX-14040
2016 · Samantha E. Yohn, Augustyna Gogoj, et al. · Pharmacology Biochemistry and Behavior · 48
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
2022 · Yifei Wang, Xiangjun Tian, et al. · Molecular Cancer Therapeutics · 41
High-Affinity Small Molecule Inhibitors of T Cell Costimulation: Compounds for Immunotherapy
2004 · Philip Huxley, Deborah H. Sutton, et al. · Chemistry & Biology · 36
PDF
Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket
1997 · Andrew Miller, Marion Askew, et al. · Bioorganic & Medicinal Chemistry Letters · 27
Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide
2024 · Mohamed El Fakiri, Anusha R. Regupathy, et al. · Theranostics · 26
PDF
Synthesis and Chirality of Novel Heterocyclic Compounds Designed for Crop Protection
1994 · H. P. Fischer, H. P. Buser, et al. · Bulletin des Sociétés Chimiques Belges · 24
Synthesis and Configuration of Some Hydroxymilbemycin Derivatives Including 22,23‐Dihydroavermectin B1b Aglycone
1990 · Bruno Frei, Philip Huxley, et al. · Helvetica Chimica Acta · 14
Abstract 5854: BT5528, a Bicycle Toxin Conjugate targeting EphA2 has potent anti-tumor activity without bleeding or coagulation abnormalities in preclinical models
2018 · Gavin Bennett, Philip Huxley, et al. · Cancer Research · 3
Abstract 5807: Bicycle Toxin Conjugates®for the treatment of solid tumors
2024 · Stephen J. Walsh, Johanna Lahdenranta, et al. · Cancer Research · 2
Abstract 1319: Rapid accumulation of cytotoxic payload in tumor tissue drives BT5528 activity in tumor models
2021 · Johanna Lahdenranta, Gavin Bennett, et al. · Cancer Research · 2
Abstract 5855: Bicycle Drug Conjugates targeting EphA2 for the treatment of solid tumors: Discovery and selection of BT5528
2018 · Gavin Bennett, Philip Huxley, et al. · Cancer Research · 2
Abstract 4601: Development and clinical translation of a phage display derived MT1-MMP-specific bicyclic peptide for radiotheranostic applications
2025 · Ann-Christin Eder, Mohamed A. Omrane, et al. · Cancer Research · 1
Abstract LB008: Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcomas (OS); Preclinical testing of BT1769, an MT1-MMP-targeted Bicycle Toxin Conjugate, in OS by the Pediatric Preclinical Testing Consortium (PPTC)
2021 · Yifei Wang, Wendong Zhang, et al. · Cancer Research · 1
Abstract B026: Targeting the novel tumor antigen MT1-MMP with Bicycle® Drug Conjugates (BDC®) for the potential treatment of NSCLC and other solid tumor indications
2025 · Steve B. Ludbrook, Stephen Walsh, et al. · Molecular Cancer Therapeutics
Preclinical evaluation of [68Ga]Ga-BCY18469, a first-in-class EphA2-targeting radiotheranostic Bicyclic Peptide
2023 · Mohamed El Fakiri, Gemma Mudd, et al. · Nuclear Medicine and Biology
Supplementary Data from Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
2023 · Yifei Wang, Xiangjun Tian, et al.
Supplementary Figure from Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
2023 · Yifei Wang, Xiangjun Tian, et al.
PDF
Data from Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
2023 · Yifei Wang, Xiangjun Tian, et al.
Works count: 34
Citation count: 1,287
H-index: 14
I10-index: 14
Year
Topic
Type